ADMA Biologics Inc (ADMA)
6.81
+0.07
(+1.04%)
USD |
NASDAQ |
May 03, 16:00
6.80
-0.01
(-0.15%)
After-Hours: 20:00
ADMA Biologics Research and Development Expense (Annual): 3.30M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.30M |
| December 31, 2022 | 3.614M |
| December 31, 2021 | 3.646M |
| December 31, 2020 | 5.907M |
| December 31, 2019 | 2.344M |
| December 31, 2018 | 3.926M |
| Date | Value |
|---|---|
| December 31, 2017 | 5.57M |
| December 31, 2016 | 7.688M |
| December 31, 2015 | 7.016M |
| December 31, 2014 | 9.517M |
| December 31, 2013 | 9.303M |
| December 31, 2012 | 3.469M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
2.344M
Minimum
2019
5.907M
Maximum
2020
3.762M
Average
3.614M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Vanda Pharmaceuticals Inc | 76.82M |
| ANI Pharmaceuticals Inc | 34.29M |
| Ligand Pharmaceuticals Inc | 24.54M |
| Johnson & Johnson | 15.08B |
| Puma Biotechnology Inc | 50.38M |